secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125390
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences Q3 net loss $21M; cash $174.4M; Phase 3 CoMpass authorized in Europe
--------------------------------------------------------------------------------

- Net loss $21.0M (Q3 2024) vs $18.5M YoY; cash $174.4M funds operations into 2H 2026.
- Phase 2 end-of-study: 80% tumor control, 90% visual acuity preservation in early-stage choroidal melanoma.
- Phase 3 CoMpass trial authorized to enroll in Europe; >100 patients pre-screened globally.
- Phase 1 NMIBC: 4/5 low-grade clinical complete responses; immune activation field effect observed.
- Appointed Sabine Brookman-May as SVP, Therapeutic Area Head Urologic Oncology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017024125390/0000950170-24-125390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017024125390/aura-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer